Pfizer Reaffirms CV Disease Commitment With Deal For Akcea's ANGPTL3 Drug

 
• By Jessica Merrill
  
Generate a summary of this article
Listen to this article
Beta

Pfizer agreed to pay $250m up front for worldwide rights to a Phase II drug that could target a broad population in cardiovascular disease. Scrip talked to Pfizer's head of internal medicine research about it.

Heart health care medical cardiovascular disease concept and organ donor donation for life giving charity campaign with healthy red love heart on aging woman's hand support - Image
Pfizer is going big and broad in cardiovascular disease • Source: Shutterstock

Pfizer Inc. is making a big play in cardiovascular/metabolic disease with a worldwide licensing deal with Akcea Therapeutics Inc. that reaffirms its commitment to the cardiovascular therapy area. The companies announced on 7 October that Pfizer will pay Akecea $250m up front for rights to an RNA-targeted antisense therapy designed to reduce the production of angiopoietin-like3 (ANGPTL3) protein, a regulator of triglycerides, cholesterol, glucose and energy metabolism.

It's a big deal for Pfizer, which lost its blockbuster-sized footing in cardiovascular disease when Lipitor (atorvastatin) went generic in...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Cardiovascular

Aerovate Tanks On Trial Catastrophe

 
• By Elizabeth Cairns

A disastrous Phase II miss for the pulmonary arterial hypertension candidate AV-101 leaves Aerovate drifting. Could Gossamer stand to benefit?    

Cagrisema Leads The Charge For 2025

 
• By Elizabeth Cairns

2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.  

Evidence Growing For GLP-1s To Treat Alzheimer’s And Parkinson’s

 
• By Andrew McConaghie

GLP-1 receptor agonists could play a big role in tackling neurodegeneration and a new academic study has raised expectations of Novo Nordisk’s latest semaglutide Phase III results

Kerendia Could Be Next Jewel In Bayer's Pharma Crown

 
• By Kevin Grogan

CEO Bill Anderson would not be drawn on whether the drug, currently approved for chronic kidney disease associated with type 2 diabetes, will hit a previous forecast of €3bn peak sales, but expansion into heart failure may make that figure look conservative.

More from Therapeutic Category

Scrip Data Article Without An Author

"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.